Chromosomal DNA and p53 Stability, Ubiquitin System and Apoptosis in B-CLL Lymphocytes

References

• Hutchison C. A., III, Peterson S. N., Gill S. R., Cline R. T., White O., Fraser C. M., Mith H. O., Venter J. C. Global transposon mutagenesis and a minimal Mycoplasma genome. Science 1999; 286: 2165–2169
   PubMed Web of Science ®Google Scholar
• Elis H. M., Horvitz H. R. Genetic control of programmed cell death in the nematode. C. elegans. Cell 1986; 44: 817–829
   PubMed Web of Science ®Google Scholar
• Ryan K. M., Ernst M. K., Rice N. R., Vousden K. H. Role of NF-κB in p53-mediated programmed cell death. Nature 2000; 404: 892–897
   PubMed Web of Science ®Google Scholar
• van Antwerp D. J., Martin S. J., Kafri T., Green D. R., Verma I. M. Suppression of TNF-a-induced apoptosis by NF-κB. Science 1996; 274: 787–789
   PubMed Web of Science ®Google Scholar
• Hanada M., Delia D., Aiello A., Stedtmauer E., Reed J. C. Bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820–1828
   PubMed Web of Science ®Google Scholar
• Reed J. C. Molecular biology of chronic lymphocytic leukemia. Seminars in Oncology 1998; 25: 11–18
   PubMed Web of Science ®Google Scholar
• Delic J., Masdehors P., Ömura S., Cosset J-M., Dumont J., Binet J-L., Magdelénat H. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo-and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis. Br. J. Cancer 1998; 77: 1103–1107
   PubMed Web of Science ®Google Scholar
• Masdehors P., Ömura S., Merle-Béral H., Mentz F., Cosset J-M., Dumont J., Magdelénat H., Delic J. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematology 1999; 105: 752–757
   PubMed Web of Science ®Google Scholar
• Chandra J., Niemer I., Gilbreath J., Kliche K. O., Andreeff M., Friereich E. J., Keating M., McConkey D. J. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998; 92: 4220–4229
   PubMed Web of Science ®Google Scholar
• Delic J., Morange M., Magdelénat H. Ubiquitin pathway involvement human lymphocyte γ-irradiation-induced apoptosis. Mol. Cell. Biol. 1993; 13: 4875–4883
   PubMed Web of Science ®Google Scholar
• Hershko A., Ciechanover A. The ubiquitin system. Ann. Rev. Biochem. 1998; 67: 425–479
   PubMed Web of Science ®Google Scholar
• Masdehors P., Glaisner S., Maciorowski Z., Magdelénat H., Delic J. Ubiquitin-dependent protein processing controls radiation-induced apoptosis through the N-end rule pathway. Exp. Cell Res. 2000; 257: 48–57
   PubMed Web of Science ®Google Scholar
• Hengartner M. O. The biochemistry of apoptosis. Nature 2000; 407: 770–776
   PubMed Web of Science ®Google Scholar
• Juliusson G., Merup M. Cytogenetics in Chronic Lymphocytic Leukemia. Seminars in Oncology 1998; 25: 19–26
   PubMed Web of Science ®Google Scholar
• Muller C., Christodoulopoulos G., Salles B., Panasci L. DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of Chronic Lymphocytic Leukemia lymphocytes to nitrogen mustards. Blood 1998; 92: 2213–2219
   PubMed Web of Science ®Google Scholar
• Christodoulopoulos G., Muller C., Salles B., Kazmi R., Panasci L. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmanin. Cancer Res. 1998; 58: 1789–1792
   PubMed Web of Science ®Google Scholar
• Gottlieb T. M., Oren M. p53 in growth control and neoplasia. Biochem. Biophys. Acta 1996; 1287: 77–102
   PubMed Web of Science ®Google Scholar
• Scheffner M., Huitbrgtse J. M., Viestra R. D., Howley P. M. The HPV-16 E6 and E6-AP complex fonctions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495–505
   PubMed Web of Science ®Google Scholar
• Ciechanover A., Shkedy D., Oren M., Bercovich B. Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of the ubiquitin-carrier protein, E2. J. Biol. Chem. 1994; 269: 9582–9589
   PubMed Web of Science ®Google Scholar
• Chowdary D. R., Dermody J. J., Jha K. K., Ozer H. L. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell Biol. 1994; 14: 1997–2003
   PubMed Web of Science ®Google Scholar
• Maki C. G., Huibergtse J. M., Howley P. M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 1996; 56: 2649–2654
   PubMed Web of Science ®Google Scholar
• Haupt Y., Maya R., Kazas A., Oren M. Mdm-2 promotes the rapid degradation of p53. Nature 1997; 387: 296–299
   PubMed Web of Science ®Google Scholar
• Kubbutat M. H., Jones S. N., Vousden K. H. Regulation of p53 stability by Mdm-2. Nature 1997; 387: 299–303
   PubMed Web of Science ®Google Scholar
• Buschmann T., Fuchs S. Y., Lee C-G., Pan Z-Q., Ronai Z. SUMO-1 mdification of Mdm2 prevents its self-ubiquitination and increases mdm2 ability to ubiquitinate p53. Cell 2000; 101: 753–762
   PubMed Web of Science ®Google Scholar
• Gonen H., Shkedy D., Barnoy S., Kosower N. S., Ciechanover A. On the involvement of calpains in the degradation of the tumor suppressor protein p53. FEBS Lett. 1997; 406: 17–22
   PubMed Web of Science ®Google Scholar
• Kubuttat M. H., Vousden K. H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell Biol. 1997; 17: 460–468
   PubMed Web of Science ®Google Scholar
• Pariat M., Carillo S., Molinari M., Salvat C., Debussche L., Bracco L., Milner J., Piechaczyk M. Proteolysis by calpains: a possible contribution to degradation of p53. Mol. Cell Biol 1997; 17: 2806–2815
   PubMed Web of Science ®Google Scholar
• Squier M. K. T., Cohen J. J. Calpain, an upstream regulator of thymocyte apoptosis. J. Immunol. 1997; 158: 3690–3697
   PubMed Web of Science ®Google Scholar
• Masdehors P., Merle-Béral H., Maloum K., Ömura S., Magdelénat H., Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 2000; 96: 269–274
   PubMed Web of Science ®Google Scholar
• Mellgren R. L. Specificities of cell permeant peptidyl inhibitors for the proteinase activities of μ-calpain and the 20S proteasome. J. Biol Chem. 1997; 272: 29899–29903
   PubMed Web of Science ®Google Scholar
• Lin K-I., Baraban J. M., Ratan R. R. Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration. Cell Death Differ. 1998; 5: 577–583
   PubMed Web of Science ®Google Scholar
• Mimnaugh E. G., Chen H. Y., Davie J. R., Celis E., Neckers L. Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response. Biochemistry 1997; 36: 14418–29
   PubMed Web of Science ®Google Scholar
• Zimmermann J., Erdmann D., Lalande I., Grossenbacher R., Noorani M., Fürst P. Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1. Oncogene 2000; 19: 2913–2920
   PubMed Web of Science ®Google Scholar
• Spataro V., Norbury C., Haris A. The ubiquitin-proteasome pathway in cancer. Br. J. Cancer 1998; 77: 448–454
   PubMed Web of Science ®Google Scholar
• Lane D. P. p53, guardian of the genome. Nature 1992; 358: 15–16
   PubMed Web of Science ®Google Scholar
• Lewine A. J. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–331
   PubMed Web of Science ®Google Scholar
• Zhou B-B. S., Elledge S. J. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433–438
   PubMed Web of Science ®Google Scholar
• Xu Y., Baltimore D. Dual role of ATM in the cellular response to irradiation and in cell growth control. Genes Dev. 1996; 10: 2383–2388
   PubMed Web of Science ®Google Scholar
• Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P. J., Moss P. A. H., Taylor A. M. R. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999; 353: 26–29
   PubMed Web of Science ®Google Scholar
• Starostik P., Manshouri T., O'Brien S., Freireich E., Kantarijan H., Haidar M., Lerner S., Keating M., Albitar M. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 1998; 58: 4552–4557
   PubMed Web of Science ®Google Scholar
• Bulrich F., Rasio D., Kitada S., Starostik P., Kipps T., Keating M., Albitar M., Reed J. C., Croce C. M. ATM mutations i B-cell chronic lymphocytic leukemia. Cancer Res. 1999; 59: 24–27
   PubMed Web of Science ®Google Scholar
• Waterman M. J., Stavridi E. S., Waterman J. L., Halazonetis T. D. ATM-dependent activation of p53 involves dephosphorylation and association with 14–3–3 proteins. Nat. Genet. 1998; 19: 175–178
   PubMed Web of Science ®Google Scholar
• Siliciano J. D., Canman C. E., Taya Y., Sakaguchi K., Appella E., Kastan M. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 1997; 15: 3471–3481
   Web of Science ®Google Scholar
• Khanna K. K., Keating K. E., Kozlov S., Scott S., Gatei M., Hobson K., Taya Y., Gabrielli B., Chan D., Lees-Miller S. P., Lavin M. F. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat. Genet. 1998; 20: 340–398
   Web of Science ®Google Scholar
• Stilgenbauer S., Schaffner C., Litterst A., Liebisch P., Gilad S., Bar-Shira A., James M. R., Lichter P., Dohner H. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat. Med. 1997; 3: 1155–1159
   PubMed Web of Science ®Google Scholar
• Stoppa-Lyonnet D., Soulier J., Lauge A., Dastot H., Garand R., Sigaux F., Stem M. H. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood 1998; 91: 3920–3926
   PubMed Web of Science ®Google Scholar
• Karlseder J., Broccoli D., Dai Y., Hardy S., De Lange T. p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999; 283: 1321–1325
   PubMed Web of Science ®Google Scholar
• Bromidge T., Lowe C., Prentice, Johnson S. p53 intronic point mutation, aberrant splicing and telomeric association in a case of B-chronic lymphocytic leukaemia. Br. J. Haematol. 2000; 111: 223–229
   PubMed Web of Science ®Google Scholar
• Westphal C. H., Rowan S., Schmaltz C., Elson A., Fisher D. E., Leder P. atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat. Genet. 1997; 16: 397–401
   PubMed Web of Science ®Google Scholar